Literature DB >> 25599014

Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.

Pascal Rouge1, Alexandra Dassonville-Klimpt1, Christine Cézard1, Stéphanie Boudesocque2, Roger Ourouda3, Carole Amant4, François Gaboriau5, Isabelle Forfar6, Jean Guillon6, Emmanuel Guillon2, Enguerran Vanquelef1, Piotr Cieplak7, François-Yves Dupradeau1, Laurent Dupont2, Pascal Sonnet1.   

Abstract

Iron chelators, through their capacity to modulate the iron concentration in cells, are promising molecules for cancer chemotherapy. Chelators with high lipophilicity easily enter into cells and deplete the iron intracellular pool. Consequently, iron-dependent enzymes, such as ribonucleotide reductase, which is over-expressed in cancer cells, become nonfunctional. A series of calix[4]arene derivatives substituted at the lower rim by ICL670, a strong FeIII chelator, have been synthesized. Physicochemical properties and antiproliferative, angiogenesis, and tumorigenesis effects of two calix[4]arenes mono- (5a) or disubstituted (5b) with ICL670 have been studied. These compounds form metal complexes in a ratio of one to two ligands per FeIII atom as shown by combined analyses of the protometric titration curves and ESIMS spectra. The grafting of an ICL670 group on a calix[4]arene core does not significantly alter the acid-base properties, but improves the iron-chelating and lipophilicity properties. The best antiproliferative and anti-angiogenic results were obtained with calix[4]arene ligand 5a, which possesses the highest corresponding properties. Analyses of molecular dynamics simulations performed on the two calix[4]arenes provide three-dimensional structures of the complexes and proved 5a to be the most stable upon complexation.

Entities:  

Keywords:  calixarenes; chelates; iron; lipophilicity; molecular dynamics

Year:  2012        PMID: 25599014      PMCID: PMC4293705          DOI: 10.1002/cplu.201200141

Source DB:  PubMed          Journal:  Chempluschem        ISSN: 2192-6506            Impact factor:   2.863


  53 in total

1.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

2.  The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.

Authors:  Karine Chantrel-Groussard; François Gaboriau; Nicole Pasdeloup; René Havouis; Hanspeter Nick; Jean-Louis Pierre; Pierre Brissot; Gérard Lescoat
Journal:  Eur J Pharmacol       Date:  2006-05-11       Impact factor: 4.432

3.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

4.  The R.E.D. tools: advances in RESP and ESP charge derivation and force field library building.

Authors:  François-Yves Dupradeau; Adrien Pigache; Thomas Zaffran; Corentin Savineau; Rodolphe Lelong; Nicolas Grivel; Dimitri Lelong; Wilfried Rosanski; Piotr Cieplak
Journal:  Phys Chem Chem Phys       Date:  2010-06-23       Impact factor: 3.676

5.  Deprotonation of calixarenes in acetonitrile.

Authors:  Ian D Cunningham; Marc Woolfall
Journal:  J Org Chem       Date:  2005-11-11       Impact factor: 4.354

6.  Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

Authors:  R A Finch; M Liu; S P Grill; W C Rose; R Loomis; K M Vasquez; Y Cheng; A C Sartorelli
Journal:  Biochem Pharmacol       Date:  2000-04-15       Impact factor: 5.858

7.  Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.

Authors:  G Lescoat; K Chantrel-Groussard; N Pasdeloup; H Nick; P Brissot; F Gaboriau
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

8.  Asymmetric induction of supramolecular helicity in calix[4]arene-based triple-stranded helicate.

Authors:  Takeharu Haino; Hidemi Shio; Ryuji Takano; Yoshimasa Fukazawa
Journal:  Chem Commun (Camb)       Date:  2009-02-26       Impact factor: 6.222

9.  Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.

Authors:  David B Lovejoy; Des R Richardson
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

10.  Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Authors:  Jiazhi Sun; Michelle A Blaskovich; Rishi K Jain; Frederic Delarue; Daniel Paris; Steven Brem; Marguerite Wotoczek-Obadia; Qing Lin; Domenico Coppola; Kihang Choi; Michael Mullan; Andrew D Hamilton; Saïd M Sebti
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

View more
  2 in total

1.  In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics.

Authors:  Axel Steinbrueck; Adam C Sedgwick; Hai-Hao Han; Michael Y Zhao; Sajal Sen; Dan-Ying Huang; Yi Zang; Jia Li; Xiao-Peng He; Jonathan L Sessler
Journal:  Chem Commun (Camb)       Date:  2021-06-08       Impact factor: 6.065

2.  Study of Iron Piperazine-Based Chelators as Potential Siderophore Mimetics.

Authors:  Pauline Loupias; Isabelle Dechamps-Olivier; Laurent Dupont; Pierre Vanlemmens; Catherine Mullié; Nicolas Taudon; Anne Bouchut; Alexandra Dassonville-Klimpt; Pascal Sonnet
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.